期刊文献+

多发性骨髓瘤患者生化试验标本分离方法的探讨 被引量:4

下载PDF
导出
摘要 目的探讨多发性骨髓瘤(Multiple Myeloma,MM)患者生化免疫试验标本的分离方法。方法在样本前处理条件且离心转速与时间相同情况下,使用普通玻璃干管,分离胶管,肝素锂抗凝管分离MM患者血清(浆)并分别检测其常用生化指标,比较其结果有无显著性差异。结果在样本前处理条件且离心转速与时间相同情况下,普通玻璃干管不能离心出足够生化检测的量的血清,使用分离胶试管,肝素锂抗凝试管则能分离出足够生化检测的量的标本。检测MM患者血清(浆)标本12项临床常用生化指标,部分结果间差异有显著性(P<0.05)。结论通过使用分离胶试管或肝素锂抗凝试管可以分离出多发性骨髓瘤(Multiple Myeloma,MM)患者足够临床生化、免疫实验用的血清(浆)标本。由分离胶试管离心产生的血清标本所做的12项临床常用生化检测结果较肝素锂抗凝试管离心产生的血浆标本偏差更小,结果更接近真实值,也更可靠。
作者 门万琪 周慧
出处 《安徽医药》 CAS 2013年第12期2115-2116,共2页 Anhui Medical and Pharmaceutical Journal
  • 相关文献

参考文献9

二级参考文献47

共引文献65

同被引文献35

  • 1Broyl A, Jongen JL, Sonneveld P. General aspects and mechanisms of peripheral neuropathy associated with bortezomib in patients with newly diagnosed multiple myelorna [ J ]. Semin Hematol, 2012,49(3) :249 -257.
  • 2Richardson PG, Delforge M, Beksac M, et al. Management of treat- ment - emergent peripheral neuropathy in multiple myeloma [ J ]. Leukemia,2012,26 (4) : 595 - 608.
  • 3Greipp PR,San Miguel J, Durie BG, et al. International staging system for multiple myeloma [ J ]. Clin Oncol, 2005,23 : 3412 - 3420.
  • 4Popat R, Oakervee HE, Hallam S, et al. Bortezomib, doxorubicin and dexamethasone (PAD) front - line treatment of multiple mye- loma: updated results after long - term follow - up [ J ]. Br J Haematol,2008,141 (4) :512 -516.
  • 5Zhang Y, Liu H, Chen X, et al. Modified bortezomib, adriamycin and dexamethasone (PAD) regimen in advanced multiple myelo- ma[ J]. Pathol Oncol Res,2014,20(4) :987 -995.
  • 6Palumbo A, Gay F, Bringhen S, et al. Bortezomib, doxorubicin and dexamethasone in advanced multiple myeloma [ J ]. Ann Oncol, 2008,19(6) :1160 - 1165.
  • 7Min H, Hui W, Ji P. Genetic polymorphism of humanCYP3A4gene in population of ban nationality in China[ J]. Chin J Clin Pharma- col Ther,2006,11 ( 3 ) : 300 - 304.
  • 8Benevolo G, Larocca A, Gentile M, et al. The efficacy and safety of bortezomib and dexamethasone as a maintenance therapy in pa- tients with advanced multiple myeloma who are responsive to sal- vage bortezomib - containing regimens [ J ]. Cancer, 2011, 117 (9) :1884 - 1890.
  • 9Miyakoshi S, Kami M, Yuji K, et al. Severe pulmonary compli - cations in Japanese patients after bortezomib treatment for refracto- ry multiple myeloma[ J]. Blood, 2006,107(9) :3492 -3494.
  • 10Gotoh A, Ohyashiki K, Oshimi K, et al. Lung injury associated with bortezomib therapy in relapsed/refractory multiple myeloma in Ja- pan : a Questionnaire - based report from the "lung injury by bort- ezomib" joint committee of the Japanese society of hematology and the Japanese society of clinical Hemato -logy[ J]. Int J Hematol, 2006,84(5) :406-412.

引证文献4

二级引证文献24

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部